bioRxivMicrobiologyPreprint
Inhibition of host N-myristoylation compromises the infectivity of SARS-CoV-2 due to Golgi-bypassing egress from lysosomes and endoplasmic reticulum
S. H. Saber, M. R. Shaker, J. Sng, N. Yak, S. D. Morrison, S. Pars, H. Zheng, G. Pietrogrande, T. Binder, S. Lu, M. Floetenmeyer, R. Ojha, T. Quirin, J. Ruuska, T. Smura, T. Strandin, R. Kant, L. Kareinen, T. Sironen, G. H. Talbo, Y. Zhu, K. Short, J. C. Mar, W. W. Kallemeijn, E. W. Tate, , M. Joensuu
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused the coronavirus disease 2019 (COVID-19) pandemic, remains a global health concern despite vaccines, neutralizing antibodies, and antiviral drugs. Emerging mutations can reduce the effectiveness of these treatments, suggesting that targeting host cell factors may be a valuable alternative. N-myristoyltransferases (NMT) are essential enzymes for protein N-myristoylation, affecting stability, interaction, localization, and function of numerous proteins. We demonstrate that selective inhibition of host cell NMT decreases SARS-CoV-2 infection by 90% in human lung and primary nasal epithelial cells, and choroid plexus-cortical neuron organoids. NMT inhibition does not affect viral entry, replication or release, but impairs the maturation and incorporation of viral envelope proteins into newly assembled virions, leading to compromised infectivity of released virions. The inhibition of host NMT triggers a Golgi-bypassing pathway for SARS-CoV-2 progeny virion egress, which occurs through endoplasmic reticulum and lysosomal intermediates.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Protein N-glycosylation is essential for SARS-CoV-2 infection
A. Casas-Sanchez, A. Romero-Ramirez, … A. Acosta-Serrano·bioRxiv·Feb 5, 2021
- Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model
L. Cornelissen, E. Hoefsmit, … C. U. Blank·bioRxiv·Nov 9, 2020
- Inactivation of the Niemann Pick C1 cholesterol transporter 1 (NPC1) restricts SARS-CoV-2 infection
P. La Rosa, J. Tiberi, … M. T. Fiorenza·bioRxiv·Dec 13, 2023
- Repurposed nystatin to inhibit SARS-CoV-2 and mutants in the GI tract
E. Virag, D. Seffer, … J. P. Pallos·bioRxiv·Oct 19, 2021
- Complete Protection from SARS-CoV-2 Lung Infection in Mice Through Combined Intranasal Delivery of PIKfyve Kinase and TMPRSS2 Protease Inhibitors
R. Kant, L. Kareinen, … G. Balistreri·bioRxiv·Jul 19, 2023
- Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection
C.-k. Oh, T. Nakamura, … S. A. Lipton·bioRxiv·Apr 5, 2022